Publications by authors named "Diana V Mazur"
Article Synopsis
- Glutamine is crucial for tumor growth, and its deprivation in solid tumors can hinder their growth and spread, particularly in human glioblastoma cell lines U87MG and T98G.
- Research indicates that U87MG cells, which have a more differentiated phenotype, show increased glycolysis and stemness marker expression (CD133) when deprived of glutamine, while T98G cells shift towards oxidative phosphorylation and become less responsive to certain drugs.
- The study highlights that metabolic and phenotypic differences between these glioblastoma cell lines lead to varying drug sensitivities, suggesting that treatment strategies should consider these differences for better outcomes.
Destroying tumor vasculature is a relevant therapeutic strategy due to its involvement in tumor progression. However, adaptive resistance to approved antiangiogenic drugs targeting VEGF/VEGFR pathway requires the recruitment of additional targets. In this aspect, targeting TRAIL pathway is promising as it is an important component of the immune system involved in tumor immunosurveillance.
View Article and Find Full Text PDFTRAIL (TNF-related apoptosis-inducing ligand) and its derivatives are potentials for anticancer therapy due to the selective induction of apoptosis in tumor cells upon binding to death receptors DR4 or DR5. Previously, we generated a DR5-selective TRAIL mutant variant DR5-B overcoming receptor-dependent resistance of tumor cells to TRAIL. In the current study, we improved the antitumor activity of DR5-B by fusion with a tumor-homing iRGD peptide, which is known to enhance the drug penetration into tumor tissues.
View Article and Find Full Text PDF